Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Regen BioPharma (RGBPP) over the last 12 years, with Q4 2025 value amounting to $1.9 million.

  • Regen BioPharma's Accumulated Expenses rose 846.42% to $1.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.9 million, marking a year-over-year increase of 846.42%. This contributed to the annual value of $1.8 million for FY2025, which is 1041.57% up from last year.
  • As of Q4 2025, Regen BioPharma's Accumulated Expenses stood at $1.9 million, which was up 846.42% from $1.8 million recorded in Q3 2025.
  • Regen BioPharma's 5-year Accumulated Expenses high stood at $1.9 million for Q4 2025, and its period low was $301363.0 during Q4 2022.
  • For the 5-year period, Regen BioPharma's Accumulated Expenses averaged around $989506.6, with its median value being $809370.5 (2021).
  • As far as peak fluctuations go, Regen BioPharma's Accumulated Expenses tumbled by 5447.23% in 2022, and later surged by 41180.76% in 2025.
  • Over the past 5 years, Regen BioPharma's Accumulated Expenses (Quarter) stood at $661934.0 in 2021, then crashed by 54.47% to $301363.0 in 2022, then rose by 19.57% to $360353.0 in 2023, then skyrocketed by 373.89% to $1.7 million in 2024, then rose by 8.46% to $1.9 million in 2025.
  • Its Accumulated Expenses stands at $1.9 million for Q4 2025, versus $1.8 million for Q3 2025 and $1.8 million for Q2 2025.